IXC 1.35% 7.5¢ invex therapeutics ltd

Ann: Invex Files Pre-IND/Type B Meeting Request with US FDA, page-5

  1. 397 Posts.
    lightbulb Created with Sketch. 53
    Well said. And as Tom mentions in the release, the team completed the study protocol and SAP within three months of obtaining final EMA feedback.

    Not sure if anyone here has been involved in the completion of study protocol/SAP plan for a Phase 3 trial, but I can tell you that this is quick.


 
watchlist Created with Sketch. Add IXC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.